Sectors
ASND
Ascendis Pharma A/S
265.57
1 x 266.20
1 x 266.35
bid
ask
+
0.35
0.13%
2 @ 05:35 PM
265.00 -0.57 (0.21%)
| Ytd | 24.54% | |
| 1y | 51.85% |
263.28
day range
268.14
160.86
52 week range
282.15
| Open | 265.79 | Prev Close | 265.22 | Low | 263.28 | High | 268.14 | Mkt Cap | 17.74B |
| Vol | 512.54K | Avg Vol | 775.62K | EPS | 8.63 | P/E | 31.34 | Forward P/E | 16.92 |
| Beta | 0.48 | Short Ratio | 3.52 | Inst. Own | 102.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 238.34 | 200-d Avg | 222.18 | 1yr Est | 297.37 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0.21 | 0.32 | 0.11 | 52.38% |
| 2026-02-11 | 2025-12 | 0 | N/A | -0.58 | -966.67% |
| 2025-11-12 | 2025-09 | 0 | N/A | -0.76 | -185.37% |
| 2025-08-07 | 2025-06 | 0 | N/A | 0.49 | 34.51% |
| 2025-05-01 | 2025-03 | 0 | N/A | -0.1 | -6.41% |
| 2025-02-12 | 2024-12 | 0 | N/A | 0.52 | 43.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-07 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-05-19 | Citigroup | Upgrade | Buy | |
| 2026-05-15 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-11 | Barclays | Upgrade | Overweight | Overweight |
| 2026-05-08 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-04-16 | B of A Securities | Upgrade | Buy | Buy |
Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-28 | BIENAIME JEAN-JACQUES | Director | 900.00 | Purchase |
| 2026-05-10 | JENSEN FLEMMING STEEN | Officer | 0.00 | Sale |
| 2026-06-01 | SMITH SCOTT THOMAS | Chief Financial Officer | 4.37K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | RA Capital Management, LLC | 10.28M | 0.00 | 16.75% |
| 2026-03-30 | venBio Select Advisor LLC | 5.06M | 0.00 | 8.25% |
| 2026-03-30 | Westfield Capital Management Company, L.P. | 4.81M | 0.00 | 7.84% |
| 2026-03-30 | FMR Inc | 3.88M | 0.00 | 6.32% |
| 2026-03-30 | Artisan Partners Limited Partnership | 3.23M | 0.00 | 5.26% |
| 2026-03-30 | Franklin Resources Inc | 2.05M | 0.00 | 3.34% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | MFS Mid Cap Growth Equity | 1.27M | 0.00 | 2.08% |
| 2026-03-30 | Capital Group Growth Fnd of Amer Comp | 1.21M | 0.00 | 1.97% |
| 2026-03-30 | American Funds Growth Fund of Amer A | 1.21M | 0.00 | 1.97% |
| 2026-03-30 | Vanguard Health Care Inv | 1.10M | 0.00 | 1.80% |
| 2026-03-30 | Franklin Innovation Composite | 1.10M | 0.00 | 1.79% |
| 2025-09-29 | Janus Henderson Mid Cap Growth MA | 976.88K | 0.00 | 1.59% |